Connor, Clark & Lunn Investment Management (CC&L)’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-24,685
| Closed | -$791K | – | 1257 |
|
|
2022
Q1 | $791K | Buy |
+24,685
| New | +$791K | ﹤0.01% | 703 |
|
|
2019
Q2 | – | Sell |
-1,026
| Closed | -$70K | – | 1101 |
|
|
2019
Q1 | $70K | Sell |
1,026
-200
| -16% | -$13.6K | ﹤0.01% | 883 |
|
|
2018
Q4 | $65K | Sell |
1,226
-848
| -41% | -$45K | ﹤0.01% | 916 |
|
|
2018
Q3 | $141K | Sell |
2,074
-500
| -19% | -$34K | ﹤0.01% | 868 |
|
|
2018
Q2 | $305K | Buy |
2,574
+524
| +26% | +$62.1K | ﹤0.01% | 880 |
|
|
2018
Q1 | $170K | Buy |
2,050
+1,432
| +232% | +$119K | ﹤0.01% | 665 |
|
|
2017
Q4 | $92K | Buy |
618
+318
| +106% | +$47.3K | ﹤0.01% | 754 |
|
|
2017
Q3 | $19K | Sell |
300
-15
| -5% | -$950 | ﹤0.01% | 798 |
|
|
2017
Q2 | $15K | Sell |
315
-55
| -15% | -$2.62K | ﹤0.01% | 804 |
|
|
2017
Q1 | $23K | Buy |
+370
| New | +$23K | ﹤0.01% | 885 |
|
|
2016
Q4 | – | Sell |
-370
| Closed | -$27K | – | 1016 |
|
|
2016
Q3 | $27K | Buy |
370
+95
| +35% | +$6.93K | ﹤0.01% | 819 |
|
|
2016
Q2 | $22K | Buy |
+275
| New | +$22K | ﹤0.01% | 852 |
|